JP2020530846A5 - - Google Patents

Download PDF

Info

Publication number
JP2020530846A5
JP2020530846A5 JP2020508317A JP2020508317A JP2020530846A5 JP 2020530846 A5 JP2020530846 A5 JP 2020530846A5 JP 2020508317 A JP2020508317 A JP 2020508317A JP 2020508317 A JP2020508317 A JP 2020508317A JP 2020530846 A5 JP2020530846 A5 JP 2020530846A5
Authority
JP
Japan
Prior art keywords
peptide
subject
myelin
disease
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020508317A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020530846A (ja
JP7419229B2 (ja
Filing date
Publication date
Priority claimed from GBGB1713037.8A external-priority patent/GB201713037D0/en
Priority claimed from GBGB1713035.2A external-priority patent/GB201713035D0/en
Priority claimed from GBGB1713036.0A external-priority patent/GB201713036D0/en
Application filed filed Critical
Priority claimed from PCT/GB2018/052304 external-priority patent/WO2019034862A1/en
Publication of JP2020530846A publication Critical patent/JP2020530846A/ja
Publication of JP2020530846A5 publication Critical patent/JP2020530846A5/ja
Application granted granted Critical
Publication of JP7419229B2 publication Critical patent/JP7419229B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020508317A 2017-08-14 2018-08-14 方法 Active JP7419229B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1713037.8A GB201713037D0 (en) 2017-08-14 2017-08-14 Method
GBGB1713035.2A GB201713035D0 (en) 2017-08-14 2017-08-14 Method
GB1713035.2 2017-08-14
GB1713037.8 2017-08-14
GB1713036.0 2017-08-14
GBGB1713036.0A GB201713036D0 (en) 2017-08-14 2017-08-14 Method
PCT/GB2018/052304 WO2019034862A1 (en) 2017-08-14 2018-08-14 Method

Publications (3)

Publication Number Publication Date
JP2020530846A JP2020530846A (ja) 2020-10-29
JP2020530846A5 true JP2020530846A5 (enExample) 2021-09-24
JP7419229B2 JP7419229B2 (ja) 2024-01-22

Family

ID=63294371

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020508317A Active JP7419229B2 (ja) 2017-08-14 2018-08-14 方法

Country Status (8)

Country Link
US (1) US20210093695A1 (enExample)
EP (1) EP3668535A1 (enExample)
JP (1) JP7419229B2 (enExample)
CN (1) CN111225681A (enExample)
AU (2) AU2018316662A1 (enExample)
CA (1) CA3072867A1 (enExample)
WO (1) WO2019034862A1 (enExample)
ZA (1) ZA202000882B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111983241B (zh) * 2020-09-04 2022-05-20 四川大学华西医院 诊断脑卒中认知障碍的蛋白标志物以及模型的训练方法
JPWO2023100758A1 (enExample) * 2021-11-30 2023-06-08

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020072493A1 (en) * 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
EP2211892B1 (en) * 2007-10-31 2011-08-03 Apitope Technology (Bristol) Limited Compositions comprising myelin basic protein peptides and medical uses thereof
GB201300684D0 (en) * 2013-01-15 2013-02-27 Apitope Int Nv Peptide
GB201300683D0 (en) * 2013-01-15 2013-02-27 Apitope Int Nv Peptide
EP3268382B1 (en) * 2015-03-09 2021-05-05 The United States of America, as represented by The Secretary, Department of Health and Human Services Myelin oligodendrocyte glycoprotein, myelin basic protein, and proteolipid protein compositions and methods of use

Similar Documents

Publication Publication Date Title
JP2019196370A5 (enExample)
JP2016535786A5 (enExample)
RU2019134341A (ru) (+)-альфа-дигидротетрабеназин для использования при лечении двигательного расстройства
JP2018509388A5 (enExample)
JPWO2019156137A5 (enExample)
JP2006506942A5 (enExample)
JP2020530846A5 (enExample)
RU2017121836A (ru) Нейродегенеративные расстройства
WO2020219486A9 (en) Collagen peptide-based medicament compositions and devices and methods of production and use thereof
CA2986891C (en) Compositions for use in treating parkinson's disease and related disorders
BR112021017203A2 (pt) Leucina, acetil leucina e análogos relacionados para o tratamento de doenças
RU2019136495A (ru) C-концевые фрагменты cdnf и маnf, фармацевтические композиции, содержащие указанные фрагменты, и применения указанных фрагментов и композиций
IL308132A (en) Methods of treatment of autoimmune disorders using ilt7 binding proteins
JP2009519025A5 (enExample)
Peng et al. Apelin‑13 ameliorates LPS‑induced BV‑2 microglia inflammatory response through promoting autophagy and inhibiting H3K9ac enrichment of TNF‑α and IL‑6 promoter
JP2018522891A5 (enExample)
Pistono et al. What’s new about oral treatments in Multiple Sclerosis? Immunogenetics still under question
RU2015134357A (ru) Пептид
JP2016528171A5 (enExample)
RU2015134356A (ru) Пептид
JP2016539911A5 (enExample)
EA202192160A1 (ru) Доставка полинуклеотида cln3 с помощью аденоассоциированного вируса
JP2009542609A5 (enExample)
EA202190724A1 (ru) Препарат на основе кетамина для лечения депрессий путём ингаляций
MX2019003720A (es) Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.